Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

actinium Ac 225 vofatamab

A radioimmunoconjugate containing vofatamab, a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the fibroblast growth factor receptor type 3 (FGFR3) labeled, via a chelating agent, with the alpha-emitting radioisotope actinium Ac 225, with potential antineoplastic activity. Upon administration of actinium Ac 225 vofatamab, the vofatamab moiety specifically targets and binds to FGFR3. Upon binding, the radioisotope moiety delivers a cytotoxic dose of alpha radiation to FGFR3-expressing tumor cells. FGFR3, a receptor tyrosine kinase upregulated or mutated in many tumor cell types, plays a key role in tumor cell proliferation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:[225Ac]-FPI-1966
[225Ac]-vofatamab
225Ac-FPI-1966
225Ac-vofatamab
actinium-225 vofatamab
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search